Moderna to Grow European Commercial Footprint
Will establish presence in Belgium, Denmark, Norway, the Netherlands, Poland and Sweden
Moderna will be expanding its commercial network across six additional countries in Europe. The biotech firm plans to establish a commercial presence in Belgium, Denmark, Norway, the Netherlands, Poland and Sweden to support the delivery of mRNA vaccines and therapeutics locally. This announcement follows the recent news of plans for four new subsidiaries in Malaysia, Taiwan, Singapore and Hong Kong.
"Europe has played a critical role in Moderna's ability to manufacture and deliver our COVID-19 vaccine across the world, protecting millions of people from COVID-19 infection, hospitalization, and death. ... I am proud of the growth we continue to achieve," said Stéphane Bancel, CEO of Moderna. "I look forward to furthering our collaborations with European researchers and partners to leverage our mRNA technology and expand treatment options to improve the lives of patients across Europe."
The company currently has operations in 12 countries across the globe and has announced plans to establish a commercial presence in another ten countries spanning Asia-Pacific and Europe in 2022.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
